Venus Remedies Q3 FY26 results: PAT up, auditor flags Germany unit risk

Going-concern doubtEmphasis of matterProfit growth above 25%Exceptional itemResults View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.9%Reaction day

₹782.00

prior close

₹820.55

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.8%+3.1% vs market

Pharmaceuticals peers, median of 157sector+0.9%+4.0% vs sector

On the reaction day the stock moved 3.1 pts more than Nifty Microcap 250 and 4.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.7

15m

-0.7

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.9+1.8+3.1+0.9+4.0

Next day

-0.5+0.5-1.0+0.4-0.9

+1.7+4.3-2.6+2.4-0.8

-0.4+5.6-6.0+3.0-3.3

-1.9+4.6-6.5+2.2-4.1

-6.6+3.8-10.4+2.1-8.8

-4.7+7.5-12.2+4.4-9.1

15d

-2.7+3.8-6.5+1.2-3.9

-15.5-0.3-15.2-0.5-15.0

+4.8-9.6+14.4-10.4+15.2

+23.5+9.9+13.6+3.2+20.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venus Remedies posted Q3 FY26 standalone revenue of Rs 179.95 cr vs Rs 172.20 cr YoY, with PAT of about Rs 25.58 cr vs Rs 19.24 cr. Consolidated 9M FY26 revenue grew to Rs 510.19 cr from Rs 455.23 cr; PAT jumped to Rs 55.31 cr from Rs 24.34 cr (prior year had Rs 9.91 cr exceptional loss). Auditor flagged going concern risk for German subsidiary Venus Pharma GmbH with negative net worth of Rs 94.15 lakhs and Rs 2,859.72 lakhs pending share application money.

Likely market impact

Strong profit growth aided by absence of prior year one-time loss; German subsidiary weakness and large pending investment are key risks.